



Caffeine regulates GABA transport via A₁R blockade and cAMP signaling

Vladimir Pedro Peralva Borges-Martins^a, Danielle Dias Pinto Ferreira^b, Arthur Cardoso Souto^a,
 Jessika Geisebel Oliveira Neto^c, Danniell Pereira-Figueiredo^d, Karin da Costa Calaza^d,
 Karen de Jesus Oliveira^c, Alex Christian Manhães^e, Ricardo Augusto de Melo Reis^f,
 Regina Célia Cussa Kubrusly^{a,*}



^a Laboratório de Neurofarmacologia, Departamento de Fisiologia e Farmacologia, Universidade Federal Fluminense, Niterói, Brazil

^b Laboratório de Doenças Neurodegenerativas, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

^c Laboratório de Fisiologia Endócrina e Metabologia, Departamento de Fisiologia e Farmacologia, Universidade Federal Fluminense, Niterói, Brazil

^d Laboratório de Neurobiologia da Retina, Departamento de Neurobiologia, Instituto de Biologia, Universidade Federal Fluminense, Niterói, Brazil

^e Laboratório de Neurofisiologia, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

^f Laboratório de Neuroquímica, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

ARTICLE INFO

Keywords:

Caffeine
 A₁R
 GAT
 Retina
 Chick
 Development

ABSTRACT

Caffeine is the most consumed psychostimulant drug in the world, acting as a non-selective antagonist of adenosine receptors A₁R and A_{2A}R, which are widely expressed in retinal layers. We have previously shown that caffeine, when administered acutely, acts on A₁R to potentiate the NMDA receptor-induced GABA release. Now we asked if long-term caffeine exposure also modifies GABA uptake in the avian retina and which mechanisms are involved in this process. Chicken embryos aged E11 were injected with a single dose of caffeine (30 mg/kg) in the air chamber. Retinas were dissected on E15 for *ex vivo* neurochemical assays. Our results showed that [³H]-GABA uptake was dependent on Na⁺ and blocked at 4 °C or by NO-711 and caffeine. This decrease was observed after 60 min of [³H]-GABA uptake assay at E15, which is accompanied by an increase in [³H]-GABA release. Caffeine increased the protein levels of A₁R without altering ADORA1 mRNA and was devoid of effects on A_{2A}R density or ADORA2A mRNA levels. The decrease of GABA uptake promoted by caffeine was reverted by A₁R activation with N6-cyclohexyl adenosine (CHA) but not by A_{2A}R activation with CGS 21680. Caffeine exposure increased cAMP levels and GAT-1 protein levels, which was evenly expressed between E11-E15. As expected, we observed an increase of GABA containing amacrine cells and processes in the IPL, also, cAMP pathway blockage by H-89 decreased caffeine mediated [³H]-GABA uptake. Our data support the idea that chronic injection of caffeine alters GABA transport via A₁R during retinal development and that the cAMP/PKA pathway plays an important role in the regulation of GAT-1 function.

1. Introduction (963 words)

Caffeine is the main psychostimulant drug consumed in the world (Heishman and Henningfield, 1992; Temple et al., 2017). Caffeine is a methylxanthine able to affect several behavioral, cognitive and physiological functions of the CNS, such as sleep, cognition, learning, memory or promoting neuroprotection (Ribeiro and Sebastiao, 2010). Indeed, caffeine (50 μM) selectively interferes on synaptic transmission and plasticity in the hippocampus through adenosine receptor

blockade, in a way that A₁R mediates the impact of caffeine on synaptic transmission while A_{2A}R regulates its impact on long term potentiation (LTP) (Lopes et al., 2019). However, doses higher than 0.5 mM are able to inhibit cyclic nucleotides phosphodiesterase enzymes, mobilize internal calcium stores and also block GABA_A receptors (Ferre, 2008; Fredholm et al., 1999; Ribeiro and Sebastiao, 2010; Williams and Jarvis, 1988). The adenosine effects are mostly linked to the activation of its metabotropic receptors, which can be classified into four cloned subtypes, namely A₁, A_{2A}, A_{2B}, and A₃ (Ribeiro et al., 2002). A₁R and

* Corresponding author. Laboratório de Neurofarmacologia, Universidade Federal Fluminense, Rua Hernani de Mello, 101 / 213 São Domingos, Niterói, RJ, 24210-130, Brazil.

E-mail addresses: vladimirppbm@gmail.com (V.P.P. Borges-Martins), ferreiradanielle@id.uff.br (D.D.P. Ferreira), arthursouto@id.uff.br (A.C. Souto), jgeisebel@gmail.com (J.G. Oliveira Neto), dannifigueiredo12@gmail.com (D. Pereira-Figueiredo), karincalaza@gmail.com (K. da Costa Calaza), karenoliveira@id.uff.br (K. de Jesus Oliveira), ac_manhaes@yahoo.com.br (A.C. Manhães), ramreis@biof.uff.br (R.A. de Melo Reis), reginakubrusly1@gmail.com, reginakubrusly1@gmail.com (R.C.C. Kubrusly).

<https://doi.org/10.1016/j.neuint.2019.104550>

Received 8 September 2019; Received in revised form 18 September 2019; Accepted 19 September 2019

Available online 26 September 2019

0197-0186/ © 2019 Elsevier Ltd. All rights reserved.